VGB3 

VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1)/VEGFR2 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model^[1].

1572.76

C₆₇H₁₀₁N₁₉O₂₁S₂

Lys-Ala-Trp-Ala-Glu-Cys-Arg-Pro-Pro-Asp-Glu-Gly-Leu-Cys (Disulfide bridge: Cys6-Cys14)

KAWAECRPPDEGLC (Disulfide bridge: Cys6-Cys14)

O=C([C@@H](N)CCCCN)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H]3CC(C)C)=O)=O)CCC(O)=O)=O)CC(O)=O)=O)CCC2)=O)CCC1)=O)CCCNC(N)=N)=O)CSSC[C@H](NC3=O)C(O)=O)=O)CCC(O)=O)=O)C)=O)CC4=CNC5=CC=CC=C45)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zanjanchi P, et al. Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity. J Nanobiotechnology. 2022 Jan 4;20(1):7.  [Content Brief]